Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTKBNASDAQ:EYPTNASDAQ:LABNASDAQ:MASS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$3.77-1.3%$4.14$3.27▼$7.63$489.33M1.41717,612 shs590,832 shsEYPTEyePoint Pharmaceuticals$6.37-2.6%$5.93$3.91▼$21.26$437.80M1.39889,177 shs805,154 shsLABStandard BioTools$1.16-5.7%$1.16$0.97▼$2.74$466.15M1.542.22 million shs710,722 shsMASS908 Devices$5.41+3.4%$3.85$1.81▼$7.48$191.14M0.3986,884 shs318,328 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences0.00%+3.29%-8.05%-34.32%-33.39%EYPTEyePoint Pharmaceuticals0.00%+12.15%+7.78%-25.32%-61.32%LABStandard BioTools0.00%0.00%+1.75%-29.70%-52.07%MASS908 Devices0.00%+14.01%+34.91%+107.28%-3.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTKBCytek Biosciences2.5736 of 5 stars3.24.00.00.03.91.70.0EYPTEyePoint Pharmaceuticals1.6991 of 5 stars3.50.00.00.03.51.70.0LABStandard BioTools3.0646 of 5 stars3.33.00.00.02.74.20.6MASS908 Devices1.1807 of 5 stars1.32.00.00.02.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTKBCytek Biosciences 2.33Hold$6.4270.20% UpsideEYPTEyePoint Pharmaceuticals 3.00Buy$26.63317.97% UpsideLABStandard BioTools 2.50Moderate Buy$2.50115.52% UpsideMASS908 Devices 2.50Moderate Buy$5.33-1.42% DownsideCurrent Analyst Ratings BreakdownLatest MASS, CTKB, LAB, and EYPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)3/22/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/19/2025CTKBCytek BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.003/7/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/6/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/6/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/4/2025CTKBCytek BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.50 ➝ $8.002/27/2025LABStandard BioToolsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Sector Weight2/19/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/6/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTKBCytek Biosciences$200.45M2.41$0.02 per share206.16$2.90 per share1.30EYPTEyePoint Pharmaceuticals$43.27M10.12N/AN/A$5.66 per share1.13LABStandard BioTools$174.43M2.52N/AN/A($1.85) per share-0.63MASS908 Devices$59.63M3.21N/AN/A$5.11 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTKBCytek Biosciences-$12.15M-$0.05N/A∞N/A-5.05%-2.58%-2.05%5/6/2025 (Estimated)EYPTEyePoint Pharmaceuticals-$70.79M-$2.31N/AN/AN/A-226.57%-43.01%-31.63%5/6/2025 (Estimated)LABStandard BioTools-$74.66M-$0.55N/AN/AN/A-79.92%-27.05%-15.52%5/6/2025 (Estimated)MASS908 Devices-$36.40M-$2.10N/AN/AN/A-109.11%-24.60%-19.23%4/29/2025 (Estimated)Latest MASS, CTKB, LAB, and EYPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTKBCytek Biosciences-$0.04N/AN/AN/A$43.18 millionN/A5/14/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65N/AN/AN/A$8.84 millionN/A5/13/2025Q1 2025MASS908 Devices-$0.29N/AN/AN/A$11.90 millionN/A5/6/2025Q1 2025LABStandard BioTools-$0.04N/AN/AN/A$40.10 millionN/A3/5/2025Q4 2024EYPTEyePoint Pharmaceuticals-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTKBCytek BiosciencesN/AN/AN/AN/AN/AEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AMASS908 DevicesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTKBCytek BiosciencesN/A6.215.47EYPTEyePoint PharmaceuticalsN/A5.505.45LABStandard BioToolsN/A3.763.41MASS908 DevicesN/A4.243.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTKBCytek Biosciences69.46%EYPTEyePoint Pharmaceuticals99.41%LABStandard BioTools53.74%MASS908 Devices88.06%Insider OwnershipCompanyInsider OwnershipCTKBCytek Biosciences9.60%EYPTEyePoint Pharmaceuticals4.74%LABStandard BioTools53.10%MASS908 Devices27.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTKBCytek Biosciences500128.10 million116.45 millionOptionableEYPTEyePoint Pharmaceuticals12068.73 million65.02 millionOptionableLABStandard BioTools620378.99 million174.59 millionOptionableMASS908 Devices6035.33 million25.18 millionOptionableMASS, CTKB, LAB, and EYPT HeadlinesRecent News About These Companies908 Devices (NASDAQ:MASS) Receives "Sell (D-)" Rating from Weiss RatingsApril 27 at 1:39 AM | marketbeat.com908 Devices (NASDAQ:MASS) Earns "Sell (D-)" Rating from Weiss RatingsApril 26 at 1:57 AM | americanbankingnews.comLeerink Partners Remains a Hold on 908 Devices (MASS)April 24 at 6:31 PM | markets.businessinsider.comMasivo Announces Drill Program at Cerro ColoradoApril 24 at 10:08 AM | newsfilecorp.comBuy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes ContinueApril 23, 2025 | zacks.com908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and MitigationApril 22, 2025 | 01net.it908 Devices reports preliminary Q1 revenue $11.5M. consensus $11.9MApril 16, 2025 | markets.businessinsider.com908 Devices Announces Preliminary First Quarter 2025 Financial ResultsApril 15, 2025 | finance.yahoo.com908 Devices expects Q1 revenue below estimatesApril 15, 2025 | msn.com908 Devices Leads These 3 Penny Stocks To ConsiderApril 10, 2025 | uk.finance.yahoo.com908 Devices (NASDAQ:MASS) Earns Sell (D-) Rating from Weiss RatingsApril 10, 2025 | marketbeat.com5 Top-Ranked Stocks of Nasdaq ETF Beating the Bear MarketApril 7, 2025 | zacks.com908 Devices Inc. (NASDAQ:MASS) Short Interest Up 26.7% in MarchApril 3, 2025 | marketbeat.comNew Strong Buy Stocks for April 1stApril 1, 2025 | zacks.comBest Momentum Stocks to Buy for March 13thMarch 13, 2025 | zacks.com908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec DeviceMarch 11, 2025 | 01net.it908 Devices gets $1.7M order from Ministry of Health of UkraineMarch 11, 2025 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for 908 Devices (MASS)March 11, 2025 | markets.businessinsider.com908 Devices (MASS) Gets a Hold from Leerink PartnersMarch 7, 2025 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on 908 Devices (MASS)March 5, 2025 | markets.businessinsider.comQ4 2024 908 Devices Inc. Earnings Call TranscriptMarch 5, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentQuantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreBy Jeffrey Neal Johnson | April 9, 2025View Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreSeismic Shift at Intel: Massive Layoffs Precede Crucial EarningsBy Jeffrey Neal Johnson | April 24, 2025View Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Stock: Weathering the Storm, Time for a Comeback?By Ryan Hasson | April 11, 2025View Rocket Lab Stock: Weathering the Storm, Time for a Comeback?MASS, CTKB, LAB, and EYPT Company DescriptionsCytek Biosciences NASDAQ:CTKB$3.77 -0.05 (-1.31%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.76 0.00 (-0.13%) As of 04/25/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.EyePoint Pharmaceuticals NASDAQ:EYPT$6.37 -0.17 (-2.60%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$6.48 +0.11 (+1.65%) As of 04/25/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Standard BioTools NASDAQ:LAB$1.16 -0.07 (-5.69%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.16 0.00 (0.00%) As of 04/25/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.908 Devices NASDAQ:MASS$5.41 +0.18 (+3.44%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.42 +0.01 (+0.18%) As of 04/25/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
